A Phase II Clinical Trial of Pembrolizumab in Combination With the AE37 Peptide Vaccine in Patients With Metastatic Triple-Negative Breast Cancer
Latest Information Update: 16 May 2022
At a glance
- Drugs AE 37 (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NSABP FB-14
- Sponsors NuGenerex Immuno-Oncology
- 28 May 2021 Status changed from recruiting to active, no longer recruiting.
- 10 Jul 2020 According to a Generex Biotechnology Corporation media release, this trial will be discussed in the investor conference call on Friday July 10th 2020.
- 16 Jan 2020 According to a Generex Biotechnology Corporation media release, the first cohort of patients has completed the initial safety evaluation for AE37/Keytruda combination therapy, and the company is looking forward to completing the patient enrollment this year.